Select Bibliography

Filter by any of these (after searching):

There are 16 items

Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on the experimental thoracic radiotherapy (TRT) arms of CALGB 30610 (Alliance) / RTOG 0538

Bogart, Jeffrey , Wang, Xiaofei , Masters, Gregory , Zhu, Han ... - ESMO - Ann Oncol - 2019

Abstract - Secondary - Primary - Respiratory - CALGB-30610

β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled in the NCCTG-N9831 (Alliance) trial

Caparica, Rafael , Ma, Yaohua , De Angelis, Claudia ... - ESMO - Annals of Oncology - 2020

Abstract - Secondary-not-in-original - Primary - Breast - NCCTG-N9831

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary - Primary - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary - Primary - GU - A031203

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

Das, Rahul K , Furchtgott, Leon , Meyerhardt, Jeffrey A. ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoires in HER2-positive breast cancer: a correlative analysis of the CALGB 40601 (Alliance) clinical trial.

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ESMO - Ann Oncol - 2019

Abstract - Secondary - Primary - Breast - CALGB-40601

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017

Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702

LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)

Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012

Abstract - Secondary-not-in-original - Primary - Respiratory - CALGB-9633

A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients

Innocenti, F , Jiang, C , Sibley, A B , Denning, S , Etheridge, A S ... - ESMO - Ann Oncol - 2018

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-80303

Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance)

Innocenti, Federico , Rashid, Naim , Mu, Wancen , Ou, Fang-Shu ... - ESMO - Annals of Oncology - 2019

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80405

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon

Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014

Abstract - Primary - Primary - GI - C80405

PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

Mayer, Erica L. , Gnant, Michael , DeMichele, Angela , Martin, Miguel ... - ESMO - Annals of Oncology - 2020

Abstract - Primary - Primary - Breast - AFT-05

Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary - Primary - Breast - N063D

Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio

Seymour, L. K. , Le Teuff, G. , Tsao, M. , Brambilla, E. ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary-not-in-original - Meta-Analysis - Respiratory - CALGB-150802 , CALGB-9633

CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy

Venook, A. , Niedzwiecki, D. , Lenz, H. , Mahoney, M. , Innocenti, F. ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary - Primary - GI - CALGB-80405